NINJ1:一种新的脓毒症严重程度和死亡生物标志物
该研究在116例脓毒症ICU患者、16例非脓毒症ICU对照和16例健康对照中检测循环NINJ1水平。脓毒症患者NINJ1升高,与SOFA、APACHE II评分及肝损伤标志物、凝血参数正相关,并与脓毒症诱导的凝血病相关。ROC分析显示NINJ1预测28天死亡优于降钙素原和C反应蛋白,但低于SOFA和APACHE II评分;NINJ1联合SOFA将AUC从0.6843提升至0.773。作者认为NINJ1可作为反映病情严重度、凝血病和死亡风险的新生物标志物,联合评分可改善风险分层,但需进一步验证研究以促进临床应用。
要点
- 在116例脓毒症ICU患者中,循环NINJ1水平较非脓毒症ICU对照和健康对照升高,且与脓毒症严重度评分正相关。
- NINJ1与肝损伤标志物(天冬氨酸转氨酶/丙氨酸转氨酶)及凝血参数(D-二聚体、活化部分凝血活酶时间、凝血酶原时间、凝血酶时间)正相关,并与脓毒症诱导的凝血病相关。
- ROC分析显示NINJ1预测28天脓毒症死亡优于传统炎症标志物降钙素原和C反应蛋白,但预测准确性低于SOFA和APACHE II评分。
- NINJ1联合SOFA将28天死亡预测的曲线下面积从0.6843提高至0.773。
- 作者认为NINJ1是反映脓毒症严重度、凝血病和死亡风险的新生物标志物,联合SOFA和APACHE II评分可增强预后风险分层,但需进一步验证研究以促进临床实施。
适用人群与场景
- 脓毒症ICU患者(116例)
- 非脓毒症ICU对照(16例)
- 健康对照(16例)
研究设计与关键结果
- 研究设计:比较脓毒症ICU患者、非脓毒症ICU对照和健康对照的血清NINJ1水平,并在脓毒症队列中分析NINJ1与临床疾病严重度评分(SOFA、APACHE II)及实验室参数的相关性,用ROC分析评估NINJ1对28天死亡的预测效能。
- 脓毒症患者循环NINJ1水平升高,且与脓毒症严重度评分正相关。
- 在脓毒症中,NINJ1与肝损伤标志物(天冬氨酸转氨酶/丙氨酸转氨酶)及凝血参数(D-二聚体、活化部分凝血活酶时间、凝血酶原时间、凝血酶时间)正相关。
- 使用国际血栓与止血学会显性弥散性血管内凝血评分系统分析显示,NINJ1与脓毒症诱导的凝血病相关。
- ROC分析显示NINJ1预测28天脓毒症死亡优于传统炎症标志物降钙素原和C反应蛋白,但预测准确性低于SOFA和APACHE II评分。
- NINJ1联合SOFA将死亡预测的曲线下面积从0.6843提高至0.773。
证据类型、等级与局限
- 证据类型:临床生物标志物研究(比较脓毒症ICU患者、非脓毒症ICU对照和健康对照,并在脓毒症队列中分析相关性及预后效能)。
- 局限:原文报告需进一步验证研究以促进临床实施。
对床旁实践的改变
- 作者认为循环NINJ1可作为反映脓毒症疾病严重度、凝血病和死亡风险的新生物标志物,其与SOFA和APACHE II评分整合可显著增强预后风险分层。
- 作者认为这些发现凸显了NINJ1用于脓毒症预后判断和监测的前景临床效用,但需进一步验证研究以促进实施。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background : Multiple cell death modalities are implicated in sepsis pathobiology. However, the clinical relevance of NINJ1, a key mediator of plasma membrane rupture during lytic cell death, in sepsis progression and outcomes has remained poorly explored. Methods: Circulating NINJ1 levels were measured in 116 septic intensive care unit (ICU) patients, 16 nonseptic ICU controls, and 16 healthy controls. Comparative analysis of serum NINJ1 across these groups was performed. Correlations between NINJ1 and clinical disease severity scores (Sequential Organ Failure Assessment [SOFA], Acute Physiology and Chronic Health Evaluation [APACHE II]) as well as laboratory parameters were examined in the sepsis cohort. Furthermore, we assessed the prognostic performance of NINJ1 for predicting 28-day mortality in septic patients using receiver operating characteristic (ROC) analyses. Results: Circulating NINJ1 levels were elevated in septic patients and positively correlated with sepsis severity scores. NINJ1 also showed positive correlations with liver injury markers (aspartate transaminase/alanine aminotransferase) and coagulation parameters (D-dimer, activated partial thromboplastin time, prothrombin time, thrombin time) in sepsis. Further analysis using the International Society on Thrombosis and Hemostasis overt disseminated intravascular coagulation scoring system revealed an association between NINJ1 and sepsis-induced coagulopathy. ROC analysis demonstrated that NINJ1 outperformed traditional inflammatory biomarkers procalcitonin and C-reactive protein in predicting 28-day sepsis mortality, although its prognostic accuracy was lower than SOFA and APACHE II scores. Combining NINJ1 with SOFA improved mortality prediction from an area under the curve of 0.6843 to 0.773. Conclusions: Circulating NINJ1 serves as a novel sepsis biomarker indicative of disease severity, coagulopathy and mortality risk, and its integration with SOFA and APACHE II scores substantially enhances prognostic risk stratification. These findings highlight the prospective clinical utility of NINJ1 for sepsis prognostication and monitoring, warranting further validation studies to facilitate implementation.
参考来源
- Wu Y, Li T, Tan S, et al. NINJ1: A NOVEL SEPSIS SEVERITY AND MORTALITY BIOMARKER. Shock. 2024. PMID: 39193891. doi:10.1097/SHK.0000000000002460
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。